



# President's Cancer Panel Current Series

*John P. Williams, MD, FACS*

*Chair*



# Members



**John P. Williams, M.D.**  
*PCP Chair*



**Edith P. Mitchell, M.D.**  
*PCP Member*



**Robert A. Ingram**  
*PCP Member*

NCI provides administrative, science writing and media/communications support



# “INNOVATION & IMPLEMENTATION”

## **PRESIDENT’S CANCER PANEL**

- Re-Introduction of PCP
- Timely cancer topics
- “Implementation”
- Digital content
- Recommendation messaging

## **COVID-19 – Cancer Screening**

- Decrease in screening
- Innovation from Disruption
- Working Groups
- Cross Cutting Themes
- Innovation
- Report Summer 2021



# “INNOVATION & IMPLEMENTATION”

- **PRESIDENT’S CANCER PANEL**

- Re-Introduction of PCP
- Timely cancer topics
- “Implementation”
- Digital content
- Recommendation messaging




# Fast Start: Early 2020 Development

- Engaged the NCI
  - Division Leaders for input
- Developed PCP Team
- Top priorities
- Implementation Science
- Early pivot to COVID-19 & cancer screening





# The NCI Team



**Maureen R. Johnson, Ph.D.**  
*Executive Secretary*



**Samantha L. Finstad, Ph.D.**  
*Senior Health Science Policy  
Advisor*



**Rebecca A. Hardesty, Ph.D.**  
*Presidential Management Fellow*



# History & Mission

- The President's Cancer Panel was established by law in 1971 when the National Cancer Act was signed by President Richard Nixon.
- 50<sup>th</sup> Anniversary in 2021
- <https://www.cancer.gov/about-nci/overview/history/national-cancer-act-1971>

*The President's Cancer Panel monitors the activities of the National Cancer Program and reports to the President of the United States on barriers to progress in reducing the burden of cancer.*




# National Cancer Program

## Stakeholders



## National Cancer Program – Digital Version










# Past & Future Reports

- Past & future reports available online
- [www.prescancerpanel.cancer.gov](http://www.prescancerpanel.cancer.gov) ([intro link](#))
- Messaging prioritization
  - Distribution reports
  - Engage media & organizations & stakeholders
  - Public engagement
- Video versions of recommendations
- PCP Implementation Success =  
Engagement & Messaging to Stakeholders





# “INNOVATION & IMPLEMENTATION”

## • COVID-19 & Cancer Screening Topic

- Dramatic decrease in screening
- Innovation from disruption
- Working groups – four tumor types
- Cross cutting themes
- Innovation
- Report Summer 2021

\*Early Stakeholder Engagement\*



# COVID-19 the Disrupter


- Disruption at all levels
  - Screening, diagnosis, treatment, research, etc.
- Health disparities are exacerbated
- During these uncertain time we are more open to change and innovation
- Widespread use and adoption of telehealth – here to stay
  - Pros and cons
- Areas where the PCP can give a push to reduce a barrier or highlight an opportunity



# Impact of COVID-19 on Cancer Screening

- Cancer screening likely the most impacted, with at one point a 90-percent reduction of cancer screenings
- Long-term impact of missed or delayed screenings will result in increased morbidity and mortality from cancer

## Modeled cumulative excess deaths from colorectal and breast cancers, 2020 to 2030\*



Modeled cumulative excess deaths from colorectal and breast cancers, 2020 to 2030\* CREDITS: (GRAPH) V. ALTOUNIAN/SCIENCE; (DATA) NATIONAL CANCER INSTITUTE

Sharpless, NE; *Science* 19 Jun 2020; Vol. 368, Issue 6497, pp. 1290



# Improving Resilience and Equity in Cancer Screening: Lessons from COVID-19 and Beyond

- Pre-COVID
  - Opportunities and barriers related to screening
- During COVID
  - Implications of pandemic on screening
  - Risk-based approach to screening
  - Opportunities and barriers related to screening
- Post-COVID
  - Getting back to screening
  - Changes in barriers from pre-COVID setting
  - Taking COVID lessons learned forward - opportunities



# 2020 Topic: Improving Resilience and Equity in Cancer Screening



## Lung Cancer Screening




Dr. Mitch Schnall, Univ of Penn  
Dr. Paul Doria-Rose, NCI  
*October 26 & 28, 2020*



## Colorectal Cancer Screening




Dr. Richard Wender, Univ of Penn  
Dr. Al B. Benson III, Northwestern  
*November 2 & 4, 2020*



## Cervical Cancer Screening



Dr. Rebecca B. Perkins, Boston University  
Dr. Nico Wentzensen, NCI  
*November 9 & 10, 2020*




## Breast Cancer Screening



Dr. Wortia McCaskill-Stevens, NCI  
Dr. Kevin Hughes, Mass General - Harvard  
*November 16 & 18, 2020*




# Working Group Process and Timeline



**Final Report anticipated in Summer 2021**



- Working Groups
- PCP Meetings
  - Virtual
- Cross Cutting Themes
- Innovation







# Improving Resilience and Equity in Cancer Screening: Lessons from COVID-19 and Beyond

- Innovations in Cancer Screening
- Cross Cutting themes
- Address existing & worsening inequities
- Actionable Recommendations
  - Prioritizing Implementation
- Report in Mid 2021
- Video & Written formats



# “INNOVATION & IMPLEMENTATION”

## • PCP & PCP Topics

- Timely & relevant
- Transparent process
- Prioritize “innovation”
- Focus on “implementation”
- Actionable recommendations
- Reports understandable & video format



# President's Cancer Panel & NCI





# Connect With Us!

- For information about our past and upcoming meetings visit:

<https://prescancerpanel.cancer.gov/>



@PresCancerPanel



YouTube Channel (soon)

